The meta-analysis showed that in the therapy of patients with NSCLC, the anti-EGFR-mAb and standard first-line chemotherapy combination provided a remarkable benefit in terms of efficacy outcomes compared to chemotherapy alone (Fig. 2A–C). This evidence concerns the gene EGFR and non-small cell lung carcinoma.